Standards of Care and Novel Approaches in the Management of Glioblastoma Multiforme

Overview

Journal Chin J Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Jan 4

PMID 24384238

Citations 74

Authors

Andreas F Hottinger

Roger Stupp

Krisztian Homicsko

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard therapeutic approaches provide modest improvement in the progression-free and overall survival, necessitating the investigation of novel therapies. We review the standard treatment options for GBM and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.

Citing Articles

Glioblastoma Therapy: Past, Present and Future.

Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J Int J Mol Sci. 2024; 25(5).

PMID: 38473776 PMC: 10931797. DOI: 10.3390/ijms25052529.

Naringenin Nanoformulations for Neurodegenerative Diseases.

Sahoo L, Tripathy N, Dilnawaz F Curr Pharm Biotechnol. 2024; 25(16):2108-2124.

PMID: 38347794 DOI: 10.2174/0113892010281459240118091137.

De Ritis ratio in elderly glioblastoma patients treated with chemoradiation: A comprehensive analysis of serum biomarkers.

Kim J, Lee H, Kim I, Lee J, Cho J, Wee C Neurooncol Adv. 2024; 6(1):vdad173.

PMID: 38288092 PMC: 10824161. DOI: 10.1093/noajnl/vdad173.

A Systematic Review of the Metabolism of High-Grade Gliomas: Current Targeted Therapies and Future Perspectives.

De Maria L, Panciani P, Zeppieri M, Ius T, Serioli S, Piazza A Int J Mol Sci. 2024; 25(2).

PMID: 38255798 PMC: 10815583. DOI: 10.3390/ijms25020724.

Engineered smart materials for RNA based molecular therapy to treat Glioblastoma.

Singh R, Mondal I, Janjua T, Popat A, Kulshreshtha R Bioact Mater. 2023; 33:396-423.

PMID: 38059120 PMC: 10696434. DOI: 10.1016/j.bioactmat.2023.11.007.

References

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Kirson E, Schneiderman R, Dbaly V, Tovarys F, Vymazal J, Itzhaki A . Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009; 9:1. PMC: 2647898. DOI: 10.1186/1756-6649-9-1. View

Kreisl T, Kim L, Moore K, Duic P, Kotliarova S, Walling J . A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009; 15(10):3617-23. PMC: 7227612. DOI: 10.1158/1078-0432.CCR-08-3071. View

Huang H, Held-Feindt J, Buhl R, Mehdorn H, Mentlein R . Expression of VEGF and its receptors in different brain tumors. Neurol Res. 2005; 27(4):371-7. DOI: 10.1179/016164105X39833. View

Jordan M, Toso R, Thrower D, Wilson L . Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993; 90(20):9552-6. PMC: 47607. DOI: 10.1073/pnas.90.20.9552. View

Raizer J, Abrey L, Lassman A, Chang S, Lamborn K, Kuhn J . A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010; 12(1):95-103. PMC: 2940554. DOI: 10.1093/neuonc/nop015. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Gerstner E, Chen P, Wen P, Jain R, Batchelor T, Sorensen G . Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010; 12(5):466-72. PMC: 2940624. DOI: 10.1093/neuonc/nop051. View

Kreisl T, Kim L, Moore K, Duic P, Royce C, Stroud I . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2008; 27(5):740-5. PMC: 2645088. DOI: 10.1200/JCO.2008.16.3055. View

10.

de Groot J, Fuller G, Kumar A, Piao Y, Eterovic K, Ji Y . Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12(3):233-42. PMC: 2940588. DOI: 10.1093/neuonc/nop027. View

11.

Sathornsumetee S, Desjardins A, Vredenburgh J, McLendon R, Marcello J, Herndon J . Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010; 12(12):1300-10. PMC: 3018944. DOI: 10.1093/neuonc/noq099. View

12.

Reardon D, Egorin M, Quinn J, Rich J, Rich Sr J, Gururangan S . Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005; 23(36):9359-68. DOI: 10.1200/JCO.2005.03.2185. View

13.

Kirson E, Dbaly V, Tovarys F, Vymazal J, Soustiel J, Itzhaki A . Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007; 104(24):10152-7. PMC: 1886002. DOI: 10.1073/pnas.0702916104. View

14.

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

15.

Wong E, Hess K, Gleason M, Jaeckle K, Kyritsis A, PRADOS M . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-8. DOI: 10.1200/JCO.1999.17.8.2572. View

16.

Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P . Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(16):2712-8. DOI: 10.1200/JCO.2009.26.6650. View

17.

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

18.

Akhavan D, Cloughesy T, Mischel P . mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010; 12(8):882-9. PMC: 2940679. DOI: 10.1093/neuonc/noq052. View

19.

Reardon D, Fink K, Mikkelsen T, Cloughesy T, ONeill A, Plotkin S . Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26(34):5610-7. DOI: 10.1200/JCO.2008.16.7510. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View